三阳型乳腺癌的临床病理学特点及辅助治疗

doi:10.11904/j.issn.1002-3070.2020.03.014

摘要/Abstract

摘要： 三阳型乳腺癌是一种较为特殊的乳腺癌类型。虽然发病率低,但是此类型乳腺癌容易发生腋窝淋巴结转移和远处转移。这些临床病理学特点引起人们的高度重视。因此,辅助治疗方案的选择成为影响三阳型乳腺癌患者预后的重要因素。本综述意在整合国内外研究结果以为三阳型乳腺癌患者提供较为合理的个体化治疗方案。

关键词: 分子分型, 三阳型乳腺癌, 辅助治疗

Abstract: Triple positive breast cancer is a special type of breast cancer.Although the incidence is low,this type of breast cancer is prone to axillary lymph node metastasis and distant metastasis.These clinicopathological characteristics have attracted great attention.Therefore,the choice of adjuvant therapy options has become an important factor affecting the prognosis of patients with triple positive breast cancer.This review is to integrate the research results from domestic and international to provide a more reasonable individualized treatment plan for patients with triple positive breast cancer.

Key words: Molecular typing, Triple positive breast cancer, Adjuvant treatment

中图分类号:

R730.5

李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.

LI Hui,PANG Da. Clinicopathological characteristics and adjuvant treatment of triple positive breast cancer[J]. Journal of Practical Oncology, 2020, 34(3): 262-265.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/262

参考文献

1 Simpson PT,Reis-Filho JS,Lakhani SR.Breast pathology:beyond morphology[J].Semin Diagn Pathol,2010,27(1):91-96.
2 周晓蝶,王健,孟刚.三阳型乳腺癌的临床病理特征和预后[J].临床与实验病理学杂志,2014,30(5):483-487.
3 汪玲,潘华锋,李琰.不同分子分型乳腺癌临床病理特征及预后分期分析[J].临床外科杂志,2019,27(3):231-234.
4 高建超,费乐学.不同分子分型的乳腺癌患者个体化用药研究[J].中国现代普通外科进展,2017,20(5):389-393.
5 卢振东,孙晓晓,谢龙祥,等.乳腺癌分子分型研究进展[J].河南大学学报(医学版),2018,37(4):229-233.
6 Arpino G,Wiechmann L,Osborne CK,et al.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family:molecularmechanism and clinical implications for endocrine therapy resistance[J].Endocr Rev,2008,29(2):217-233.
7 Prat A,Baselga J.The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2[J].Nat Clin Pract Oncol,2008,5(9):531-542.
8 Ben VC,Isabelle VB,Maria D,et al.Axillary lymph node status of operable breast cancers by combined steroid receptor and HER2 status:triple positive tumours are more likely lymph node positive[J].Breast Cancer Res Treat,2009,113(1):181-187.
9 Alwan NAS,Mualla FH,Al Naqash M,et al.Clinical and pathological characteristics of triple positive breast cancer among Iraqi patients[J].Gulf J Oncolog,2017,1(25):2078-2101.
10 谢菲,王珏,朱倩男,等.乳腺癌分子分型与腋窝淋巴结转移的临床研究[J].中国肿瘤外科杂志,2018,10(3):147-149.
11 Simon SD,Bines J,Werutsky G,et al.Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil:The AMAZONA retrospective cohort study[J].The Breast,2019,44:113-119.
12 Chas M,Boivin L,Arbion F,et al.Clinicopathologic predictors of lymph node metastasis in breast cancer patients according to molecular subtype[J].Gynecol Obstet Hum Reprodt,2018,47(1):9-15.
13 Arpino G,Weiss H,Lee AV,et al.Estrogen receptor-positive,progesterone receptor-negative breast cancer:association with growth factor receptor expression and tamoxifen resistance[J].J Natl Cancer Inst,2005,97(17):1254-1261.
14 Parise CA,Caggiano V.Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers[J].J Cancer Epidemiol,2014,2014:469251.
15 Purdie CA,Quinlan P,Jordan LB,et al.Progesterone receptor expression is an independent prognostic variable in early breast cancer:a population-based study[J].Br J Cancer,2014,110(3):565-572.
16 Hayashi N,Niikura N,Yamauchi H,et al.Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer[J].Breast Cancer Res Treat,2013,137(2):523-531.
17 汪霖,孟祥宁.人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J].实用肿瘤学杂志,2016,30(3):266-270.
18 Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
19 Kaufman B,Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
20 Iancu G,Vasile D,Iancu RC,et al.“Triple positive” breast cancer-a novel category?[J].Rom J Morphol Embryol,2017,58(1):21-26.
21 Vici P,Pizzuti L,Natoli C,et al.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras(1):a real-world multicenter observational analysis.The RETROHER study[J].Breast Cancer Res Treat,2014,147(3):599-607.
22 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊疗指南与规范(2017版)[J].中国癌症杂志,2017,27(9):695-760.
23 Denduluri N,Somerfield MR,Eisen A,et al.Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2(HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers:an American Society of Clinical Oncology Guideline adaptation of the Cancer Care Ontario Clinical Practice Guideline[J].J Clin Oncol,2016,34(20):2416-2427.
24 Gianni L,Pienkowski T,Im YH,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer(NeoSphere):a randomised multicentre,open-label,phase 2 trial[J].Lancet Oncol,2012,13(1):25-32.
25 Schneeweiss A,Chia S,Hickish T,et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:a randomized phase II cardiac safety study(TRYPHAENA)[J].Ann Oncol,2013,24(9):2278-2284.
26 Grazia A,Carolina G,Heidi W,et al.Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy[J].J Natl Cancer Inst,2007,99(9):694-705.
27 Finn RS,Dering J,Conklin D,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J].Breast Cancer Res,2009,11(5):77.

[1]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[2]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[3]	胡琳, 沈佳. GDF-15在预测和监控表柔比星/环磷酰胺-多西他赛-曲妥珠单抗辅助治疗HER-2阳性乳腺癌患者产生心脏毒性中的作用[J]. 实用肿瘤学杂志, 2019, 33(4): 340-345.
[4]	杨梅健, 宝莹娜综述, 赵建国审校. 直肠癌的新辅助治疗[J]. 实用肿瘤学杂志, 2016, 30(5): 453-457.
[5]	刘恩瑞,任欢,赵宇(综述),苏君(审校). 胶质母细胞瘤经典亚型特征性基因变异的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 136-139.
[6]	杨利利, 艾秀清, 贺春钰, 朱相露, 木妮热·木沙江. 621例乳腺浸润性导管癌患者分子分型与临床病理学特征的关系[J]. 实用肿瘤学杂志, 2015, 29(1): 34-38.
[7]	宋金洁,王涛,边莉,郭芸菲,张少华,吴世凯,宋三泰,江泽飞. 曲妥珠单抗联合蒽环类药物应用于Her-2阳性乳腺癌的新辅助治疗初步临床研究[J]. 实用肿瘤学杂志, 2013, 27(2): 97-98.
[8]	李静, 姜达. Luminal A型乳腺癌治疗进展[J]. 实用肿瘤学杂志, 2011, 25(5): 486-489.
[9]	张瑾, 张霄蓓. 唑来膦酸在乳腺癌辅助治疗领域的临床研究进展[J]. 实用肿瘤学杂志, 2010, 24(4): 305-307.
[10]	陈桂林;谢榕;黄燕玲. Ⅰ、Ⅱ期宫颈癌预后相关因素分析[J]. 实用肿瘤学杂志, 2003, 17(02): 121-122.